Guidelines for good practice of carbapenems;Recommandations de bon usage des carbapénèmes

Antibiotiques

Volumn 12, Issue 4, 2010, Pages 183-189

  Gauzit, R ^a   Gutmann, L ^b   Brun Buisson, C ^c   Jarlier, V ^d   Fantin, B ^e  

^a HÔTEL DIEU   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^c HENRI MONDOR HOSPITAL   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e BEAUJON HOSPITAL   (France)

Author keywords

Antimicrobial resistance; Beta lactamases; Carbapenems; Guidelines

Indexed keywords

CARBAPENEM; EXTENDED SPECTRUM BETA LACTAMASE;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTICLE; DRUG USE; GOOD CLINICAL PRACTICE; GRAM NEGATIVE BACTERIUM; NONHUMAN; PRACTICE GUIDELINE;

EID: 78650304700     PISSN: 12945501     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antib.2010.09.002     Document Type: Article

References (19)

1. Giamarellou H., Poulakou G. Multidrug-resistant Gram-negative infections: what are the treatment options?. Drugs 2009, 69:1879-1901.
2. Zanhel G.G., Wiebe R., Dilay L., et al. Comparative review of the carbapenems. Drugs 2007, 67:1027-1052.
3. Nicolau D.P. Carbapenems: a potent class of antibiotics. Expert Opin Pharmacother 2008, 9:23-37.
4. Rodríguez-Martínez J.M., Poirel L., Nordmann P. Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2009, 53:4783-4788.
5. Nouer S.A., Nucci M., de-Oliveira M.P., Pellegrino F.L., et al. Risk factors for acquisition of multidrug-resistant Pseudomonas aeruginosa producing SPM metallo-beta-lactamase. Antimicrob Agents Chemother 2005, 49:3663-3667.
6. Schwaber M.U., Klarfeld-Lidji S., Navon-Venezia S., et al. Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect on mortality. Antimicrob Agents Chemother 2008, 52:1028-1033.
7. Paterson D.L., Depestel D.D. Doripenem. Clin Infect Dis 2009, 49:291-298.
8. Paramythiotou E., Lucet J.C., Timsit J.F., et al. Acquisition of multidrug-resistant Pseudomonas aeruginosa in intensive care units: role of antibiotics with antipseudomonal activity. Clin Infect Dis 2004, 38:670-677.
9. Dalhoff A., Janjic N., Echols R. Redefining penems. Biochem Pharmacol 2006, 71:1085-1095.
10. Lister P.D. Carbapenems in USA: focus on doripenem. Exp Rev Anti Infect Ther 2007, 5:793-809.
11. Livermore D.M., Musthaq S., Warner M. Selectivity of ertapenem Pseudomonas aeruginosa mutants cross-resistant to other cabapenems. J Antimicrob Chemother 2005, 55:306-311.
12. El Solh A.A., Alhajhusain A. Update on the treatment of Pseudomonas aeruginosa pneumonia. J Antimicrob Chemother 2009, 64:229-238.
13. Joseph J., Rodvold K.A. The role of carbapenem in the treatment of severe nosocomial respiratory tract infections. Expert Opin Parmacother 2008, 9:561-575.
14. Chastre J., Wunderink R., Prokocimer P., et al. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study. Crit Care Med 2008, 36:1089-1096.
15. Jaccard C., Troillet N., Harbath S., et al. Prospective randomized comparison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis. Antimicrob Agents Chemother 1998, 42:2966-2972.
16. Lucasti C., Jasovich A., Umeh O., et al. Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III prospective multicenter randomized double-blind noninferiority study. Clin Ther 2008, 30:868-883.
17. Noel V., Wolff M., Lortholary O. Bonnes pratiques de l'antibiothérapie probabiliste chez l'adulte immunodéprimé. Antibiothérapie des états septiques sévères 2004, 75-102. Elsevier, Paris.
18. Roberts J.A., Lipman J. Pharmacokinetic issue for antibiotics in the critically ill patients. Crit Care Med 2009, 37:840-851.
19. Mentzelopoulos S.D., Pratikaki M., Platsouka E., et al. Prolonged use of carbapenems and colistin predisposes to ventilator-associated pneumonia by pandrug-resistant Pseudomonas aeruginosa. Intensive Care Med 2007, 33:1524-1532.